SAN DIEGO, Feb. 3, 2023 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. IVVD common stock between November 29, 2021 and December 14, 2021, inclusive (the “Class Period”). Captioned Brill v. Invivyd, Inc., No. 23-cv-10254 (D. Mass.), the Invivyd class action lawsuit charges Invivyd as well as certain of its top executives with violations of the Securities Exchange Act of 1934.
http://www.rgrdlaw.com for more information. (PRNewsFoto/Robbins Geller Rudman & Dowd LLP)” alt=”Robbins Geller, with 200 lawyers in ten offices, represents U.S. and international institutional investors in contingency-based securities and corporate litigation. The firm has obtained many of the largest securities class action recoveries in history, including the largest securities class action judgment. Please visit http://www.rgrdlaw.com for more information. (PRNewsFoto/Robbins Geller Rudman & Dowd LLP)”>
If you suffered substantial losses and wish to serve as lead plaintiff, please provide your information here:
https://www.rgrdlaw.com/cases-invivyd-inc-f-k-a-adagio-therapeutics-inc-class-action-lawsuit-ivvd.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] Lead plaintiff motions for the Invivyd class action lawsuit must be filed with the court no later than April 3, 2023.
CASE ALLEGATIONS: Invivyd formed in June 2020, during some of the worst days of the pandemic, to develop drugs for the treatment and prevention of COVID-19 and future coronavirus outbreaks. During the Class Period, Invivyd was focused on developing ADG20, an investigational monoclonal antibody treatment for COVID-19. In September 2022, Adagio announced that it was changing its corporate name to Invivyd.
But as the Invivyd class…
